source
- AstraZeneca says phase 3 ADC shows strong overall survival despite missing progression-free survival endpointAstraZeneca executives emphasized that the detailed data from their phase 3 study of the next‑generation antibody‑drug conjugate are robust enough to be presented to regulators, even though the tri…
- Genmab reports phase 3 success for Elahere competitor and previews Merus buyout dataGenmab disclosed at the European Society for Medical Oncology meeting that its experimental therapy, positioned as a rival to Elahere, achieved a positive outcome in a phase 3 trial. The result si…